3
项与 anti-CD19 CAR T-cell therapy ( Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences ) 相关的临床试验Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
In this single-center, open-label, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. CD19 CAR T cells will be administered by i.v. injection as a using a "split dose" (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with chemotherapy resistant or refractory CD19+ ALL.
100 项与 anti-CD19 CAR T-cell therapy ( Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences ) 相关的临床结果
100 项与 anti-CD19 CAR T-cell therapy ( Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences ) 相关的转化医学
100 项与 anti-CD19 CAR T-cell therapy ( Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences ) 相关的专利(医药)
100 项与 anti-CD19 CAR T-cell therapy ( Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences ) 相关的药物交易